Cargando…

Comment on Lachenmeier et al (2020) “Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?”: disputation on various points in the publication

This Correspondence article is a counterstatement to a Brief Report published by Lachenmeier and co-workers on 17th February 2020 in F1000Research: “Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?”. This counterstatement proposes that the authors of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kruse, Daniel, Beitzke, Bernhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	F1000 Research Limited 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445557/ https://www.ncbi.nlm.nih.gov/pubmed/32864108 http://dx.doi.org/10.12688/f1000research.25354.1

Ejemplares similares

Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?
por: Lachenmeier, Dirk W., et al.
Publicado: (2023)

A protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆(9)-tetrahydrocannabinol (THC) by vaporisation
por: Solowij, Nadia, et al.
Publicado: (2014)

Conversion of Cannabidiol (CBD) into Psychotropic Cannabinoids Including Tetrahydrocannabinol (THC): A Controversy in the Scientific Literature
por: Golombek, Patricia, et al.
Publicado: (2020)

The Effect of Orally Administered Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) on Obesity Parameters in Mice
por: Eitan, Adi, et al.
Publicado: (2023)

Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition
por: Arkell, Thomas R., et al.
Publicado: (2019)

Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis
por: Hutten, Nadia R. P. W., et al.
Publicado: (2022)

Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD)
por: Meyer, Thomas, et al.
Publicado: (2019)

Proteome-Wide Profiling Using Sample Multiplexing of a Human Cell Line Treated with Cannabidiol (CBD) and Tetrahydrocannabinol (THC)
por: Abyadeh, Morteza, et al.
Publicado: (2023)

Motor neuron development in zebrafish is altered by brief (5-hr) exposures to THC (∆(9)-tetrahydrocannabinol) or CBD (cannabidiol) during gastrulation
por: Ahmed, Kazi T., et al.
Publicado: (2018)

Differences in Inhibitory Control and Resting Brain Metabolism between Older Chronic Users of Tetrahydrocannabinol (THC) or Cannabidiol (CBD)—A Pilot Study
por: Rudroff, Thorsten, et al.
Publicado: (2022)

A Critical Review of the Role of the Cannabinoid Compounds Δ(9)-Tetrahydrocannabinol (Δ(9)-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment
por: Jones, Éamon, et al.
Publicado: (2020)

Study of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) extraction FROM dried oral fluid spots (DOFS) and LC–MS/MS detection
por: Gorziza, Roberta, et al.
Publicado: (2021)

Evaluation of the preclinical analgesic efficacy of naturally derived, orally administered oil forms of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and their 1:1 combination
por: Linher-Melville, Katja, et al.
Publicado: (2020)

Efficacy of Δ(9) -Tetrahydrocannabinol (THC) Alone or in Combination With a 1:1 Ratio of Cannabidiol (CBD) in Reversing the Spatial Learning Deficits in Old Mice
por: Nidadavolu, Prakash, et al.
Publicado: (2021)

Biomechanical Effects of Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD), the Major Constituents of Cannabis, in a Sprague Dawley Rat Achilles Tendon Surgical Repair Model
por: Stauch, Chris M., et al.
Publicado: (2020)

Differential Effects of D9 Tetrahydrocannabinol (THC)- and Cannabidiol (CBD)-Based Cannabinoid Treatments on Macrophage Immune Function In Vitro and on Gastrointestinal Inflammation in a Murine Model
por: Yekhtin, Zhanna, et al.
Publicado: (2022)

Pilot clinical and pharmacokinetic study of Δ(9)-Tetrahydrocannabinol (THC)/Cannabidiol (CBD) nanoparticle oro-buccal spray in patients with advanced cancer experiencing uncontrolled pain
por: Clarke, Stephen, et al.
Publicado: (2022)

Response to Salaspuro and Lachenmeier, 2020, letter to the editor in Archives of Toxicology
por: Hartwig, Andrea, et al.
Publicado: (2020)

Cannabidiol (CBD) and Δ(9)-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial
por: Suraev, Anastasia, et al.
Publicado: (2020)

O006 Acute effects of combined cannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC) in insomnia disorder: A randomised, placebo-controlled trial using high-density EEG
por: Suraev, A, et al.
Publicado: (2022)

Biomechanical Effects of Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD), the Major Constituents of Cannabis, on Tendon to Tendon Healing in a Sprague Dawley Rat Achilles Tendon Surgical Repair Model
por: Stauch, Chris, et al.
Publicado: (2020)

CBD, a precursor of THC in e-cigarettes
por: Czégény, Zsuzsanna, et al.
Publicado: (2021)

Long-Term Consequences of Adolescent Exposure to THC-Rich/CBD-Poor and CBD-Rich/THC-Poor Combinations: A Comparison with Pure THC Treatment in Female Rats
por: Gabaglio, Marina, et al.
Publicado: (2021)

Cannabidiol (CBD) in Cancer Management
por: O’Brien, Kylie
Publicado: (2022)

The Impact of THC and CBD in Schizophrenia: A Systematic Review
por: Ahmed, Saeed, et al.
Publicado: (2021)

Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
por: Hardy, Janet, et al.
Publicado: (2020)

THC and CBD: Villain versus Hero? Insights into Adolescent Exposure
por: Pintori, Nicholas, et al.
Publicado: (2023)

Towards Better Delivery of Cannabidiol (CBD)
por: Millar, Sophie Anne, et al.
Publicado: (2020)

Cannabidiol (CBD) and Insomnia : Literature review
por: Gutierrez Higueras, T., et al.
Publicado: (2022)

The use of cannabidiol (CBD) as an analgesic component
por: Petersen, Kristian Kjær-Staal, et al.
Publicado: (2023)

Acute human exposure assessment to tetrahydrocannabinol (Δ(9)‐THC)
por: Arcella, Davide, et al.
Publicado: (2020)

The Dark Side of Cannabidiol: The Unanticipated Social and Clinical Implications of Synthetic Δ(8)-THC
por: Geci, Michael, et al.
Publicado: (2023)

Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios
por: Englund, Amir, et al.
Publicado: (2022)

Inhibition of Nicotine Metabolism by Cannabidiol (CBD) and 7-Hydroxycannabidiol (7-OH-CBD)
por: Nasrin, Shamema, et al.
Publicado: (2023)

A Review on Studies of Marijuana for Alzheimer’s Disease – Focusing on CBD, THC
por: Kim, Seok Hee, et al.
Publicado: (2019)

Potency and Therapeutic THC and CBD Ratios: U.S. Cannabis Markets Overshoot
por: Pennypacker, Sarah D., et al.
Publicado: (2022)

Identification of ∆9-tetrahydrocannabinol (THC) impairment using functional brain imaging
por: Gilman, Jodi M., et al.
Publicado: (2022)

Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain)
por: Boehnke, Kevin F., et al.
Publicado: (2022)

The Anti-Inflammatory Effects of Cannabidiol (CBD) on Acne
por: Peyravian, Nadia, et al.
Publicado: (2022)

Dispensary Cannabidiol (CBD): Nothing to Worry About!
por: Elliott, Taylor, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m9i6a9migavlsruib68225hrjk